202 related articles for article (PubMed ID: 30148829)
21. [Single vs double stem cell transplantation for the treatment of multiple myeloma].
Tamura H
Nihon Rinsho; 2015 Jan; 73(1):85-9. PubMed ID: 25626310
[TBL] [Abstract][Full Text] [Related]
22. When to recommend a second autograft in patients with relapsed myeloma?
Ziogas DC; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2017 Apr; 58(4):781-787. PubMed ID: 27894207
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.
Kansagra A; Gonsalves WI; Gertz MA; Buadi FK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Kapoor P; Muchtar E; Kourelis TV; Warsame R; Leung N; Zeldenrust SR; Lust JA; Rajkumar SV; Kyle RA; Hogan W; Kumar SK
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2127-2132. PubMed ID: 29656139
[TBL] [Abstract][Full Text] [Related]
24. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
Moreau P; Giralt SA
Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
[TBL] [Abstract][Full Text] [Related]
25. Relapsed multiple myeloma: who benefits from salvage autografts?
Chow AW; Lee CH; Hiwase DK; To LB; Horvath N
Intern Med J; 2013 Feb; 43(2):156-61. PubMed ID: 22757772
[TBL] [Abstract][Full Text] [Related]
26. Second autologous transplant as salvage therapy in multiple myeloma.
Atanackovic D; Schilling G
Br J Haematol; 2013 Dec; 163(5):565-72. PubMed ID: 24111632
[TBL] [Abstract][Full Text] [Related]
27. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
28. Management of multiple myeloma in the newly diagnosed patient.
Mateos MV; San Miguel JF
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):498-507. PubMed ID: 29222298
[TBL] [Abstract][Full Text] [Related]
29. Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.
Kumar SK; Buadi FK; Rajkumar SV
Blood; 2019 Feb; 133(7):652-659. PubMed ID: 30587528
[TBL] [Abstract][Full Text] [Related]
30. Multiple myeloma: Role of autologous transplantation.
Ntanasis-Stathopoulos I; Gavriatopoulou M; Kastritis E; Terpos E; Dimopoulos MA
Cancer Treat Rev; 2020 Jan; 82():101929. PubMed ID: 31770695
[TBL] [Abstract][Full Text] [Related]
31. Deferring autologous stem cell transplantation for consolidation of minimal residual disease in multiple myeloma.
Braunstein M; Niesvizky R
Semin Oncol; 2016 Dec; 43(6):709-711. PubMed ID: 28061993
[TBL] [Abstract][Full Text] [Related]
32. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.
Voorhees PM; Usmani SZ
Clin Adv Hematol Oncol; 2016 Sep; 14(9):719-28. PubMed ID: 27673290
[TBL] [Abstract][Full Text] [Related]
33. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
34. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.
Moreau P; Avet-Loiseau H; Harousseau JL; Attal M
J Clin Oncol; 2011 May; 29(14):1898-906. PubMed ID: 21482979
[TBL] [Abstract][Full Text] [Related]
35. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
36. Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
Maybury B; Cook G; Pratt G; Yong K; Ramasamy K
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1926-1937. PubMed ID: 27288955
[TBL] [Abstract][Full Text] [Related]
37. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
38. Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience.
Samaras P; Blickenstorfer M; Haile SR; Siciliano RD; Petrausch U; Mischo A; Zweifel M; Honegger H; Schanz U; Stussi G; Taverna C; Bauer S; Knuth A; Stenner-Liewen F; Renner C
Swiss Med Wkly; 2011; 141():w13203. PubMed ID: 21630163
[TBL] [Abstract][Full Text] [Related]
39. Multiple myeloma.
Harousseau JL; Shaughnessy J; Richardson P
Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
[TBL] [Abstract][Full Text] [Related]
40. [Induction therapy of transplant-eligible patients in multiple myeloma].
Konishi J; Sunami K
Nihon Rinsho; 2015 Jan; 73(1):90-4. PubMed ID: 25626311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]